DALLAS, TX–(Mar 14, 2014) – “The Traders Network Show” broadcasted live from Clear Channel Business Talk Radio DFW 1190 AM KFXR is proud to announce the interview recap of special guest President, David Cantor of Vycor Medical, Inc. (“Vycor”) (OTCBB: VYCO), a medical device company with a suite of FDA cleared products.
To hear the entire exclusive Clear Channel Interview click on archive link below:
Archive Interview: (11min, 3sec)http://www.yorbamedia.com/images/stories/audio/TN012314SEG1.mp3
In this fascinating interview, President David Cantor introduced Vycor and its notable ownership of over 55 patents — 38 granted and 17 pending.
Mr. Cantor went into its anchor products, ViewSite™ Brain Access System (“VBAS”), a suite of clear cylindrical disposable devices which provide neurosurgeons with a stable, minimally invasive working channel to access targeted sites within the brain, such as tumors. To date, the Company estimates more than 5,000 surgeries have been performed utilizing VBAS. A video explaining the attributes of Vycor Medical’s VBAS can be seen athttp://player.vimeo.com/video/39766887.
Cantor said, “Our device not only saves lives, but it also saves money through reduced surgeon time. We estimate that between operating time and early patient discharge those savings amount to up to $6,000 per procedure.” He went on to say that, “According to the American Association of Neurosurgeons, there are about 200,000 procedures annually that our device would be applicable for, with about another 130,000 identified through product extensions. On a worldwide basis, that would equate to a market potential for the device of about $700 million.” VBAS has regulatory approval in the United States, Europe, China, Japan, Korea and Canada and currently the Company is turning its attention to other large markets such as Russia and India.
Cantor also discussed Vycor’s wholly-owned NovaVision subsidiary, which is the worldwide leader in the field of vision rehabilitation for vision loss resulting from neurological damage and the largest such provider by far in the U.S., Europe, and other global markets. NovaVision’s VRT™ is the only medical device aimed at the restoration of vision for neurologically induced vision loss which has FDA 510 (K) clearance to be marketed in the U.S. VRT™ has been clinically proven to restore vision.
Regarding VRT™, Cantor stated, “The number of potential patients is truly amazing. A staggering 30% of stroke patients suffer from some form of vision disability. In the US, there are 8 million people who have suffered a stroke, and every year there is another 700,000 stroke victims, which puts our addressable market in the U.S. alone above $1 billion, and a worldwide target of $8 billion.” A video explaining the attributes of Vycor’s NovaVision can be seen at: http://player.vimeo.com/video/39765566
Cantor closed the interview but giving a brief overview of their recently launched productNeuroEyeCoach™, a new Internet-based “direct to the patient” saccadic eye training program that is complementary to VRT™. NeuroEyeCoach™ has been specifically developed with world-renowned professors in the field to increase the efficiency of eye movement and train the patient to make the most of their remaining vision.
About Clear Channel: Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.
About Michael Yorba: Mr. Yorba is the founder of Yorba Media and featured host on Clear Channel. For the past six years he has been integrally involved with producing and hosting a daily talk show called Commodity Classics, and The Traders Network.
From the fast action of the trading pit… to the power brokers making the headlines… Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps investors and consumers asking for more… The Traders Network stays ahead of the curve by featuring leading market and business professionals, sophisticated technology, and the analytics needed to identify the most lucrative investment strategies. Successful performance depends on finding the right opportunities. So… shift your thinking and join us as we deliver “tomorrow’s ideas today” on Clear Channel’s The Traders Network Monday – Friday from 1:00pm – 3:00pm CST live after Glenn Beck.
About Vycor Medical, Inc.
Vycor Medical, Inc. (“Vycor”) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA-cleared medical solutions that are changing and improving lives every day. The Company operates two wholly-owned business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.
Vycor Medical’s flagship, ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. Vycor Medical is ISO 13485:2003 compliant, has FDA 510(K) clearance for VBAS for brain and spine surgeries and regulatory approvals for brain surgeries in Australia, Canada, China, Europe, Japan, Korea and Russia. For an overview of Vycor Medical’s VBAS see http://player.vimeo.com/video/39766887
NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any ophthalmologist, optometrist, neurologist or physiatrist. VRT also has CE Marking for the EU. NovaVision also recently launched NeuroEyeCoach™, a new Internet-based “direct to the patient” saccadic eye training program. The Company also provides Neuro-Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect. For an overview of NovaVision see: http://player.vimeo.com/video/39765566
For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com or www.novavision.com
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
A www.1800PublicRelations.com PR Event
